title: Comparative study on the in vitro performance of blister molded and conventional lornoxicam immediate release liquitablets: accelerated stability study and anti-inflammatory and ulcerogenic effects.
abstract: BACKGROUND
  Lornoxicam is a potent non-steroidal anti-inflammatory drug (NSAID). It shows limited solubility in the gastric pH, delayed bioavailability and pharmacodynamic effects with aggravated gastric side effects (due to longer residence in the stomach wall).
  
  
  OBJECTIVE
  To enhance dissolution of lornoxicam in the gastric fluid and expectedly absorption and pharmacological action, with less ulcerogenic effects.
  
  
  METHODS
  Formulation of immediate release (IR) lornoxicam liquitablets containing both liquid and solid release modulators (wetting agent, solubilizers and microenvironmental pH modifiers). Beside the traditional direct compression technique employed for the preparation of liquitablets a new technique, blister molding, was also used. The effect of the two different manufacturing methods on the fast release characteristics (rapid disintegration and dissolution) was studied. Stability and pharmacological activity of the optimum formula were also explored.
  
  
  RESULTS
  Similarity factor pointed out the superiority of molding technique in enhancing dissolution of lornoxicam owing to significant crystallinity reduction (XRD). Optimum formula showed negligible change in drug content and dissolution profiles over 12 weeks, significantly improved anti-inflammatory activity and significantly reduced gastric ulcerative effect over pure lornoxicam and commercial formula.
  
  
  CONCLUSIONS
  Blister molded lornoxicam liquitablet of improved dissolution and pharmacological activity and less gastric erosion was successfully prepared.
authors: a Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy , Cairo University , Cairo , Egypt.
authors: Doaa Ahmed
authors: DA
authors: El-Setouhy
authors: a Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy , Cairo University , Cairo , Egypt.
authors: Alaa Abdel-Rahman
authors: AA
authors: Gamiel
authors: a Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy , Cairo University , Cairo , Egypt.
authors: Alia Abd El-Latif
authors: AA
authors: Badawi
authors: b Department of Medical Pharmacology, Faculty of Medicine , Cairo University , Cairo , Egypt.
authors: Afaf Sayed
authors: AS
authors: Osman
authors: b Department of Medical Pharmacology, Faculty of Medicine , Cairo University , Cairo , Egypt.
authors: Dina Ahmed
authors: DA
authors: Labib
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy*; D003692:Delayed-Action Preparations / Q000737:chemistry*; D004339:Drug Compounding; D065546:Drug Liberation; D004355:Drug Stability; D010894:Piroxicam / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use; D051381:Rats; D012995:Solubility; D013607:Tablets; D014456:Ulcer / Q000139:chemically induced
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D003692:Delayed-Action Preparations; D013607:Tablets; D010894:Piroxicam; C059451:lornoxicam
keywords: IR tablets; Liquitablets; dissolution enhancement; lornoxicam